Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.
Three patterns show up across ABBOTT LABORATORIES's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the deals below are the evidence.
13 acquisitions. Each entry carries the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.
Exact Sciences is a leader in large and fast-growing cancer screening and precision oncology diagnostics, best known for the Cologuard colorectal cancer screening test and the Oncotype DX cancer recurrence assays. approximately $21 billion equity value (about $23 billion including net debt).
Abbott has repeatedly taken on the world's most challenging health issues and made a meaningful impact on the lives of people in areas such as diabetes, cardiovascular disease and infectious disease. With Exact Sciences, we will do the same in cancer.Robert B. Ford — Chairman and CEO, Abbott
With the legacy and deep expertise of the Exact Sciences team, we're ready to transform cancer care.Abbott management — Exact Sciences completion release
St. Jude Medical is a global medical device company with leading positions in cardiac rhythm management, atrial fibrillation, heart failure and neuromodulation. approximately $25 billion equity value ($46.75 cash + 0.8708 Abbott shares per share, ~$85/share; ~$30 billion total value including debt).
Bringing together these two great companies will create a premier medical device business and immediately advance Abbott's strategic and competitive position.Miles D. White — Chairman and CEO, Abbott
Alere is a global leader in point-of-care diagnostics, providing rapid tests across infectious disease, cardiometabolic and toxicology testing close to the patient. $51 per share, approximately $5.3 billion at close (originally announced at $56 per share / ~$5.8 billion equity value).
We want to offer our customers the best and broadest diagnostics solutions. Alere helps us do that.Miles D. White — Chairman and CEO, Abbott
Our leading platforms and global presence in point-of-care diagnostics, combined with Abbott's broad portfolio of market-leading products, position the combined company for strong growth.Namal Nawana — President and CEO, Alere
CFR Pharmaceuticals is a Latin America-based branded generics pharmaceutical company with a broad portfolio of well-known, trusted products and a strong presence across the fast-growing region. approximately $2.9 billion.
By adding CFR's portfolio of well-known, trusted products, Abbott has taken another key step in actively shaping its portfolio to better meet the evolving needs of health care.Abbott — CFR completion news release
Solvay Pharmaceuticals is the pharmaceuticals business of the Solvay Group, with a diversified portfolio of branded specialty pharmaceutical products and a strong international, particularly emerging-markets, footprint. EUR 4.5 billion (approximately $6.2 billion) in cash, plus potential additional payments.
Piramal's Healthcare Solutions business is a leading branded generics pharmaceutical operation in India with a broad product portfolio and extensive local distribution. $2.2 billion up-front plus $400 million annually for four years beginning in 2011 (approximately $3.72 billion total).
Advanced Medical Optics is a leader in eye care, holding the number one position in LASIK surgical devices, number two in the cataract surgical device market and number three in the contact lens care market. $22.00 per share, approximately $2.8 billion including debt.
Guidant's vascular intervention and endovascular solutions businesses, including coronary and peripheral stent and angioplasty product lines, acquired from Boston Scientific as a condition of Boston Scientific's acquisition of Guidant. approximately $4.1 billion (acquired from Boston Scientific in connection with its acquisition of Guidant).
Kos Pharmaceuticals is a specialty pharmaceutical company focused on cardiometabolic and respiratory products, including the Niaspan and Advicor lipid-management franchises. $78.00 per share in cash (approximately $3.7 billion).
BASF's pharmaceutical business, operated as Knoll Pharmaceuticals, including the global operations and an early-stage anti-inflammatory antibody (later commercialized by Abbott as HUMIRA). approximately $6.9 billion in cash.
Vysis is a genomic disease management company specializing in molecular cytogenetic and FISH-based diagnostic products for cancer and genetic disease. $30.50 per share in cash (approximately $355 million).
i-STAT Corporation is a maker of handheld point-of-care blood analysis systems used at the patient's bedside. $15.35 per share in cash (approximately $392 million).
Facet Biotech is a biotechnology company with a portfolio of biologic drug candidates, including programs in multiple sclerosis and oncology and an antibody-engineering platform. $27.00 per share in cash (approximately $450 million; net of cash ~$722 million enterprise / ~$450M net).